Shin Sugimoto

This inventor holds 6 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Kowa Company Limited. Active years: 2019-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shin Sugimoto. Retrieved from https://idiyas.com/inventor/shin-sugimoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 11)

% Patents Active = 83.3

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 1.7

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

6 out of 605

Kowa Company Limited

patents

Years Active: 2019-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11759456 - Pharmaceutical composition (2023-09-19),

2. 11730719 - Pharmaceutical composition (2023-08-22),

3. 11419855 - Pharmaceutical preparation (2022-08-23),

4. 11406621 - Pharmaceutical composition (2022-08-09),

5. 11298340 - Pharmaceutical composition (2022-04-12),

6. 10376523 - Aqueous composition containing ripasudil, or a salt, or a solvate thereof (2019-08-13),

Title: The Innovative Contributions of Shin Sugimoto

Introduction

Shin Sugimoto is a prominent inventor based in Fuji, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 6 patents. His work focuses on developing pharmaceutical compositions that enhance the efficacy and stability of medications.

Latest Patents

Among his latest patents, Shin Sugimoto has developed a pharmaceutical composition containing pemafibrate, a salt thereof, or a solvate thereof, which exhibits excellent homogeneity. This composition includes pemafibrate in an amount ranging from 0.017 to 4.2 mass % in terms of the free form of pemafibrate relative to the total mass of the pharmaceutical composition. Additionally, he has created another pharmaceutical composition that contains pemafibrate, a salt thereof, or a solvate thereof, which demonstrates excellent stability with a moisture content of 2.4 mass % or less.

Career Highlights

Shin Sugimoto is currently associated with Kowa Company Limited, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing the development of effective drug formulations.

Collaborations

Shin collaborates with Akito Minamizono, contributing to the innovative projects at Kowa Company Limited.

Conclusion

Shin Sugimoto's contributions to pharmaceutical innovations highlight his expertise and commitment to improving medication formulations. His patents reflect a dedication to enhancing drug stability and efficacy, making a significant impact in the field.

Profile summary based on public USPTO records.